公开(公告)号：US20110110861A1

公开(公告)日：2011-05-12

申请号：US12989947

申请日：2009-05-01

申请人： Mireille Hanna Lahoud ,  Irina Caminschi ,  Ken Shortman ,  Jian-Guo Zhang ,  Mark Francis Van Delft ,  David Ching Siang Huang ,  Mark Dexter Wright

发明人： Mireille Hanna Lahoud ,  Irina Caminschi ,  Ken Shortman ,  Jian-Guo Zhang ,  Mark Francis Van Delft ,  David Ching Siang Huang ,  Mark Dexter Wright

IPC分类号： A61K49/00 ,  A61K39/395 ,  A61K39/00 ,  A61P35/00 ,  A61P25/00 ,  A61K31/7088 ,  A61P37/00 ,  A61P31/00 ,  G01N33/53 ,  G01N33/566 ,  C07K14/435

CPC分类号： C07K14/4726 ,  A61K31/711 ,  A61K31/713 ,  C07K16/2851 ,  C07K2319/02 ,  C07K2319/43 ,  C07K2319/90 ,  G01N33/5308 ,  G01N2333/705 ,  G01N2510/00

摘要： The present invention relates to methods of modulating the uptake and/or clearance of cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof, which can be used to treat and/or prevent diseases such as cancer, autoimmunity and infections. The present invention also relates to methods of modulating antigen recognition, processing and/or presentation, as well as immune responses to material derived from cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof. The present invention further relates to methods of detecting cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof.

摘要翻译： 本发明涉及调节受破坏的细胞膜，感染病原体的细胞，死亡细胞或死细胞或其部分的细胞的摄取和/或清除的方法，其可用于治疗和/或预防疾病 如癌症，自身免疫和感染。 本发明还涉及调节抗原识别，加工和/或表达的方法以及对具有破裂的细胞膜的细胞衍生的材料，病原体感染的细胞，死亡细胞或死细胞或其部分的免疫应答 。 本发明还涉及检测细胞破裂的细胞，病原体感染细胞，染色细胞或死细胞或其一部分的方法。

公开(公告)号：US20120039806A1

公开(公告)日：2012-02-16

申请号：US13203682

申请日：2010-03-22

申请人： Mireille Hanna Lahoud ,  Irina Caminschi ,  Jian-Guo Zhang ,  Mark Francis Van Delft ,  David Ching Siang Huang ,  Nicos Anthony NIcola ,  Alan Cowman ,  Mark Dexter Wright

发明人： Mireille Hanna Lahoud ,  Irina Caminschi ,  Jian-Guo Zhang ,  Mark Francis Van Delft ,  David Ching Siang Huang ,  Nicos Anthony NIcola ,  Alan Cowman ,  Mark Dexter Wright

IPC分类号： A61K49/00 ,  A61K9/48 ,  A61K39/00 ,  A61K47/00 ,  G01N33/567 ,  C12N5/10 ,  C12N1/21 ,  C12N1/19 ,  C12N15/63 ,  A61P37/00 ,  A61P35/00 ,  A61K38/17 ,  A61K31/7088 ,  C07K14/00 ,  C07K16/00 ,  A61P37/08 ,  A61P31/00 ,  A61P33/02 ,  A61P29/00 ,  A61K9/127

CPC分类号： G01N33/573 ,  A61K39/385 ,  A61K47/64 ,  A61K47/6801 ,  A61K2039/505 ,  A61K2039/6031 ,  C07K14/47 ,  C07K16/2851 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2317/626 ,  G01N2333/4724 ,  G01N2333/9015 ,  G01N2800/52 ,  G01N2800/56 ,  Y02A50/412

摘要： The present invention relates to the identification of proteins which bind the dendritic cell marker known as Clec9A. The present invention provides new compounds for targeting therapeutic agents such as antigens to dendritic cells. Also provided are methods of modulating a humoral and/or T cell mediated immune response to the antigen, methods of delivery of a cytotoxic agent to dendritic cells thereof involved in diseased states, methods of modulating the uptake and/or clearance of cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof, and methods of modulating antigen recognition, processing and/or presentation, as well as immune responses to material derived from cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof.

摘要翻译： 本发明涉及结合称为Clec9A的树突细胞标记物的蛋白质的鉴定。 本发明提供了用于将治疗剂如抗原靶向树突状细胞的新化合物。 还提供了调节对抗原的体液和/或T细胞介导的免疫应答的方法，将细胞毒剂递送至涉及患病状态的树突状细胞的方法，调节受破坏的细胞的摄取和/或清除细胞的方法 细胞膜，感染病原体的细胞，死亡细胞或死细胞或其部分，以及调节抗原识别，加工和/或表达的方法以及对具有破裂的细胞膜的细胞衍生的物质的免疫应答，细胞 感染病原体，死亡细胞或死细胞，或其一部分。

公开(公告)号：US20100087436A1

公开(公告)日：2010-04-08

申请号：US12464685

申请日：2009-05-12

申请人： Philip Bardwell ,  Tariq Ghayur ,  Jijie Gu ,  Ingela Beatrice Vikstrom ,  Andrew Mark Lew ,  David Matthew Tarlinton ,  Emma Margarele Carrington ,  David Ching Siang Huang

发明人： Philip Bardwell ,  Tariq Ghayur ,  Jijie Gu ,  Ingela Beatrice Vikstrom ,  Andrew Mark Lew ,  David Matthew Tarlinton ,  Emma Margarele Carrington ,  David Ching Siang Huang

IPC分类号： A61K31/5377 ,  A61K31/497

CPC分类号： A61K31/5377 ,  A61K31/44 ,  A61K31/497 ,  A61K38/13

摘要： Methods of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection are disclosed.

摘要翻译： 公开了预防或治疗器官，造血干细胞或骨髓移植排斥的方法。

公开(公告)号：US09045800B2

公开(公告)日：2015-06-02

申请号：US12704165

申请日：2010-02-11

申请人： Dimitri Semizarov ,  Tamar Uziel ,  David Ching Siang Huang ,  Mark F. van Delft ,  Christin Tse ,  Richard R. Lesniewski

发明人： Dimitri Semizarov ,  Tamar Uziel ,  David Ching Siang Huang ,  Mark F. van Delft ,  Christin Tse ,  Richard R. Lesniewski

IPC分类号： C12Q1/68 ,  C12P21/06

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/57496 ,  G01N2333/4703

摘要： The invention is directed to methods and kits that allow for identifying, classifying, and monitoring cancer patients for Bcl-2 family inhibitor therapies. The methods and compositions of the invention are directed to determining amplification of Bcl-xL and in cancer or tumor cells, or elevated Bcl-xL polypeptide expression.

摘要翻译： 本发明涉及允许鉴定，分类和监测癌症患者Bcl-2家族抑制剂疗法的方法和试剂盒。 本发明的方法和组合物涉及确定Bcl-xL和癌症或肿瘤细胞中的扩增或升高的Bcl-xL多肽表达。

公开(公告)号：US20100234239A1

公开(公告)日：2010-09-16

申请号：US12704165

申请日：2010-02-11

申请人： Dimitri Semizarov ,  Tamar Uziel ,  David Ching Siang Huang ,  Mark F. van Delft ,  Christin Tse ,  Richard R. Lesniewski

发明人： Dimitri Semizarov ,  Tamar Uziel ,  David Ching Siang Huang ,  Mark F. van Delft ,  Christin Tse ,  Richard R. Lesniewski

IPC分类号： C40B30/04 ,  C12Q1/68 ,  G01N33/53

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/57496 ,  G01N2333/4703

摘要： The invention is directed to methods and kits that allow for identifying, classifying, and monitoring cancer patients for Bcl-2 family inhibitor therapies. The methods and compositions of the invention are directed to determining amplification of Bcl-xL and in cancer or tumor cells, or elevated Bcl-xL polypeptide expression.

摘要翻译： 本发明涉及允许鉴定，分类和监测癌症患者Bcl-2家族抑制剂疗法的方法和试剂盒。 本发明的方法和组合物涉及确定Bcl-xL和癌症或肿瘤细胞中的扩增或升高的Bcl-xL多肽表达。

公开(公告)号：US07572900B2

公开(公告)日：2009-08-11

申请号：US10479307

申请日：2002-05-30

申请人： Andreas Strasser ,  Hamsa Puthalakath ,  Andreas Villunger ,  Leigh Coultas ,  Jennifer Beaumont ,  Lorraine Ann O'Reilly ,  David Ching Siang Huang

发明人： Andreas Strasser ,  Hamsa Puthalakath ,  Andreas Villunger ,  Leigh Coultas ,  Jennifer Beaumont ,  Lorraine Ann O'Reilly ,  David Ching Siang Huang

IPC分类号： C07H21/04

CPC分类号： C07K14/4747 ,  A01K2217/05 ,  A61K38/00

摘要： The present invention relates generally to novel molecules capable of, inter alia, modulating apoptosis in mammalian cells and to genetic sequences encoding same. More particularly, the present invention relates to a novel member of the Bcl-2 family of proteins, referred to herein as “Bmf”, and to genetic sequences encoding same and to regulatory sequences such as a promoter sequence directing expression of Bmf. Bmf comprises a BH3 domain which facilitates interaction to pro-survival Bcl-2 family members thereby triggering apoptosis. Bmf is regarded, therefore, as a BH3-only molecule. The molecules of the present invention are useful, for example, in therapy, diagnosis, antibody generation and as a screening tool for therapeutic agents capable of modulating physiological cell death or survival and/or modulating cell cycle entry. The present invention further contemplates genetically modified animals in which one or both alleles of Bmf are mutated or partially or wholly deleted alone or in combination with a mutation in one or both alleles of another Bcl-2-type molecule such as but not limited to Bim. The genetically modified animals are useful inter alia in screening for agents which ameliorate the symptoms of diseases caused by defects in apoptosis or which specifically promote apoptosis of target cells.

摘要翻译： 本发明一般涉及能够特别调节哺乳动物细胞凋亡和编码其的遗传序列的新型分子。 更具体地，本发明涉及Bcl-2家族蛋白质的新成员，本文称为“Bmf”，以及编码它们的遗传序列以及调节序列，例如引导Bmf表达的启动子序列。 Bmf包含BH3结构域，其促进与生存Bcl-2家族成员的相互作用，从而引发细胞凋亡。 因此，Bmf被认为是仅BH3分子。 本发明的分子可用于例如治疗，诊断，抗体产生以及作为能够调节生理细胞死亡或生存和/或调节细胞周期进入的治疗剂的筛选工具。 本发明进一步考虑了遗传修饰的动物，其中Bmf的一个或两个等位基因单独突变或部分或全部缺失，或与另一个Bcl-2型分子的一个或两个等位基因中的突变组合，例如但不限于Bim 。 遗传修饰的动物尤其可用于筛选改善由凋亡缺陷引起的疾病症状或特异性促进靶细胞凋亡的药剂。

公开(公告)号：US20090048164A1

公开(公告)日：2009-02-19

申请号：US11993829

申请日：2006-06-23

申请人： Peter Malcolm Colman ,  David Ching Siang Huang ,  Erinna Faith Lee ,  Walter Douglas Fairlie

发明人： Peter Malcolm Colman ,  David Ching Siang Huang ,  Erinna Faith Lee ,  Walter Douglas Fairlie

IPC分类号： A61K38/00 ,  G01N33/566 ,  C07K14/00 ,  A61P31/00

CPC分类号： C07K14/47 ,  A61K38/00

摘要： The present invention relates generally to therapeutic molecules which are useful for modulating apoptosis in a target cell or cell population. More particularly, the present invention provides therapeutic agents which inhibit pro-survival molecules and which are capable of inducing or facilitating apoptosis of a target cell or cell population such as cancer cells. The present invention further provides methods for generating or selecting the therapeutic molecules and pharmaceutical compositions comprising the therapeutic molecules.

摘要翻译： 本发明一般涉及可用于调节靶细胞或细胞群体中凋亡的治疗分子。 更具体地，本发明提供了抑制前体存活分子并且能够诱导或促进靶细胞或细胞群如癌细胞的凋亡的治疗剂。 本发明还提供了用于产生或选择包含治疗分子的治疗分子和药物组合物的方法。

公开(公告)号：US08686110B2

公开(公告)日：2014-04-01

申请号：US11993829

申请日：2006-06-23

申请人： Peter Malcolm Colman ,  David Ching Siang Huang ,  Erinna Faith Lee ,  Walter Douglas Fairlie

发明人： Peter Malcolm Colman ,  David Ching Siang Huang ,  Erinna Faith Lee ,  Walter Douglas Fairlie

IPC分类号： C07K5/00 ,  C12N15/00

CPC分类号： C07K14/47 ,  A61K38/00

摘要： The present invention relates generally to therapeutic molecules which are useful for modulating apoptosis in a target cell or cell population. More particularly, the present invention provides therapeutic agents which inhibit pro-survival molecules and which are capable of inducing or facilitating apoptosis of a target cell or cell population such as cancer cells. The present invention further provides methods for generating or selecting the therapeutic molecules and pharmaceutical compositions comprising the therapeutic molecules.

摘要翻译： 本发明一般涉及可用于调节靶细胞或细胞群体中凋亡的治疗分子。 更具体地，本发明提供了抑制前体存活分子并且能够诱导或促进靶细胞或细胞群如癌细胞的凋亡的治疗剂。 本发明还提供了用于产生或选择包含治疗分子的治疗分子和药物组合物的方法。

公开(公告)号：US20100197711A1

公开(公告)日：2010-08-05

申请号：US12678836

申请日：2007-09-27

申请人： Keith Geoffrey Watson ,  Guillaume Laurent Lessene ,  Jonathan Bayldon Baell ,  David Ching Siang Huang ,  Ian Philip Street ,  Jerry McKee Adams ,  Peter Malcolm Colman ,  Brad Edmund Sleebs ,  Brian John Smith ,  Peter Edward Czabotar

发明人： Keith Geoffrey Watson ,  Guillaume Laurent Lessene ,  Jonathan Bayldon Baell ,  David Ching Siang Huang ,  Ian Philip Street ,  Jerry McKee Adams ,  Peter Malcolm Colman ,  Brad Edmund Sleebs ,  Brian John Smith ,  Peter Edward Czabotar

IPC分类号： A61K31/428 ,  C07D277/82 ,  C07D417/12 ,  C12N5/09 ,  A61K31/506 ,  A61K31/4439 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00 ,  A61P35/02 ,  A61P19/02

CPC分类号： C07D417/12 ,  C07D277/82 ,  C07D417/14

摘要： The present invention relates to benzothiazole compounds that mimic the activity of BH3 only proteins and are capable of binding to and neutralizing pro survival Bcl 2 proteins. The invention also relates to the use of such compounds in the regulation of cell death or cell survival and the treatment and/or prophylaxis of diseases or conditions associated with the deregulation of cell death or cell survival.

摘要翻译： 本发明涉及苯并噻唑化合物，其类似于仅BH3蛋白的活性并且能够结合和中和生存的Bcl 2蛋白。 本发明还涉及这些化合物在调节细胞死亡或细胞存活以及治疗和/或预防与细胞死亡或细胞存活失调相关的疾病或病症中的用途。